Ahern, Elizabeth http://orcid.org/0000-0002-2062-5695
Cubitt, Annette
Ballard, Emma
Teng, Michele W. L.
Dougall, William C.
Smyth, Mark J.
Godbolt, David
Naidoo, Rishendran
Goldrick, Amanda
Hughes, Brett G. M.
Article History
Received: 28 May 2019
Accepted: 3 December 2019
First Online: 19 December 2019
Ethics approval and consent to participate
: The study (protocol, including qualitative and quantitative aspects, and trial materials including patient information and consent form) was reviewed and approved by the Human Research Ethics Committee of the Royal Brisbane and Women’s Hospital, Australia (reference number HREC/QRBW/43659) on 6th September 2018. This multisite approval covered all trial sites (comprising Royal Brisbane and Women’s Hospital, The Prince Charles Hospital, Princess Alexandra Hospital and Mater Adults Hospital). Informed consent will be obtained from all study participants.
: Not applicable.
: ESA has received travel grants from Amgen and Bristol Myers Squibb. MJS has Scientific Research Agreements with Bristol Myers Squibb and Tizona Therapeutics and is on the Scientific Advisory Boards of Tizona Therapeutics and Compass Therapeutics. AG is an employee of Amgen. BGMH is an Advisory Board Member for Merck Sharp & Dohme, Bristol Myers Squibb, AstraZenica, Pfizer, Roche, Boehringer Ingelheim, and Eisai.